• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Comment on: "Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode".对《柠檬酸铁作为治疗高磷血症的一线磷结合剂的净预算影响：马尔可夫微观模拟模型》的评论
Drugs R D. 2017 Sep;17(3):487-488. doi: 10.1007/s40268-017-0185-9.
2
Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model.柠檬酸铁作为治疗高磷血症一线磷结合剂的净预算影响：马尔可夫微观模拟模型
Drugs R D. 2017 Mar;17(1):159-166. doi: 10.1007/s40268-016-0163-7.
3
The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.维持性透析患者中，柠檬酸铁磷酸盐结合剂与矿物质代谢及炎症标志物：一项随机临床试验预设分析的结果
Am J Kidney Dis. 2015 Sep;66(3):479-88. doi: 10.1053/j.ajkd.2015.03.013. Epub 2015 May 7.
4
Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients.临床应用柠檬酸铁作为磷酸盐结合剂治疗儿科透析患者的经验。
Pediatr Nephrol. 2018 Nov;33(11):2137-2142. doi: 10.1007/s00467-018-3999-y. Epub 2018 Jun 28.
5
Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.柠檬酸铁作为终末期肾病透析患者磷结合剂的三阶段、58周试验的原理与研究设计。
Hemodial Int. 2013 Jan;17(1):67-74. doi: 10.1111/j.1542-4758.2012.00711.x. Epub 2012 Jun 15.
6
Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.柠檬酸铁治疗血液透析患者高磷血症的剂量反应和疗效：一项短期随机试验。
Am J Kidney Dis. 2013 May;61(5):759-66. doi: 10.1053/j.ajkd.2012.11.041. Epub 2013 Jan 29.
7
Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis.在接受透析的终末期肾病患者中，柠檬酸铁与活性对照相比的依从率。
Hemodial Int. 2017 Apr;21(2):243-249. doi: 10.1111/hdi.12487. Epub 2016 Sep 12.
8
Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.柠檬酸铁横跨终末期肾病的矿物质代谢和贫血领域：疗效与安全性数据综述
Expert Rev Clin Pharmacol. 2014 Nov;7(6):705-10. doi: 10.1586/17512433.2014.960848. Epub 2014 Sep 22.
9
Can ferric citrate lead to iron overload in peritoneal dialysis patients?
.柠檬酸铁会导致腹膜透析患者铁过载吗？
Clin Nephrol. 2020 May;93(5):262-266. doi: 10.5414/CN109738.
10
Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study.柠檬酸铁制剂（一种磷结合剂）对接受血液透析的慢性肾脏病 - 矿物质和骨异常患者氧化应激的影响：一项初步研究。
Biol Pharm Bull. 2016;39(6):1000-6. doi: 10.1248/bpb.b15-01021.

本文引用的文献

1
Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model.柠檬酸铁作为治疗高磷血症一线磷结合剂的净预算影响：马尔可夫微观模拟模型
Drugs R D. 2017 Mar;17(1):159-166. doi: 10.1007/s40268-016-0163-7.
2
Novel iron-containing phosphate binders for treatment of hyperphosphatemia.用于治疗高磷血症的新型含铁磷酸盐结合剂。
Expert Opin Pharmacother. 2015;16(14):2179-91. doi: 10.1517/14656566.2015.1079622. Epub 2015 Aug 18.
3
Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data.基于随机临床试验数据，柠檬酸铁（一种铁基磷酸盐结合剂）可降低透析患者的医疗成本。
Drugs R D. 2015 Sep;15(3):271-9. doi: 10.1007/s40268-015-0103-y.
4
Ferric citrate controls phosphorus and delivers iron in patients on dialysis.柠檬酸铁可控制透析患者的磷水平并提供铁元素。
J Am Soc Nephrol. 2015 Feb;26(2):493-503. doi: 10.1681/ASN.2014020212. Epub 2014 Jul 24.
5
Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.预算影响分析——良好实践原则：ISPOR 2012 预算影响分析良好实践 II 工作组报告。
Value Health. 2014 Jan-Feb;17(1):5-14. doi: 10.1016/j.jval.2013.08.2291. Epub 2013 Dec 13.
6
The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle.美国透析护理的DOPPS实践监测：综合治疗实施两年后贫血管理趋势的最新情况
Am J Kidney Dis. 2013 Dec;62(6):1213-6. doi: 10.1053/j.ajkd.2013.09.006. Epub 2013 Oct 17.
7
Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model.促红细胞生成素刺激剂与柠檬酸铁静脉铁剂使用量减少：一种管理式医疗成本抵消模型
Int J Nephrol Renovasc Dis. 2013 Apr 30;6:79-87. doi: 10.2147/IJNRD.S40729. Print 2013.
8
Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.维持性透析患者的药丸负担、依从性、高磷血症及生活质量
Clin J Am Soc Nephrol. 2009 Jun;4(6):1089-96. doi: 10.2215/CJN.00290109. Epub 2009 May 7.

Comment on: "Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode".

作者信息

Rascati Karen

机构信息

Health Outcomes and Pharmacy Practice Division, College of Pharmacy, The University of Texas, 1 University Station A1930, Austin, TX, 78712-0127, USA.

出版信息

Drugs R D. 2017 Sep;17(3):487-488. doi: 10.1007/s40268-017-0185-9.

DOI:10.1007/s40268-017-0185-9
PMID:28528515
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5629126/
Abstract
摘要